New product: Trixeo Aerosphere (formoterol fumarate dihydrate/budesonide/glycopyrronium) 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension
Trixeo Aerosphere is licensed as maintenance treatment in adults with moderate to severe COPD who are not adequately treated by a combination of inhaled corticosteroid & long-acting beta2-agonist or combination of long-acting beta2-agonist & long-acting muscarinic antagonist.
Source:
electronic Medicines compendium
SPS commentary:
Launch of this new inhaler is alongside the launch of Bevespi Aerosphere (glycopyrronium bromide/formoterol fumarate dihydrate) 7.2 micrograms/5 micrograms pressurised inhalation, suspension; which is licensed as maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.